Detailed Research on RAF Proto-Oncogene Serine/Threonine-Pipeline Review, H1 2016

RAF Proto-Oncogene Serine/Threonine-Protein KinaseC-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Complete report available @ RAF Proto-Oncogene Serine/Threonine-Protein KinaseC-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1-Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1)
- The report reviews RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) development landscape 

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

Basilea Pharmaceutica AG Eli Lilly and Company F. Hoffmann-La Roche Ltd. Hanmi Pharmaceuticals, Co. Ltd. Millennium Pharmaceuticals, Inc. Novartis AG Redx Pharma Plc Sirnaomics, Inc. VG Life Sciences, Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###